APA (7th ed.) Citation

PCL, F., B, B., G, P., G, B., CS, A., JP, F., . . . TA, P. (2026). Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. Neurology, 106(1), e214441. https://doi.org/10.1212/WNL.0000000000214441

Chicago Style (17th ed.) Citation

PCL, Ferreira, et al. "Evaluating Plasma P-tau217 as an Endpoint for Alzheimer Disease Clinical Trials." Neurology 106, no. 1 (2026): e214441. https://doi.org/10.1212/WNL.0000000000214441.

MLA (9th ed.) Citation

PCL, Ferreira, et al. "Evaluating Plasma P-tau217 as an Endpoint for Alzheimer Disease Clinical Trials." Neurology, vol. 106, no. 1, 2026, p. e214441, https://doi.org/10.1212/WNL.0000000000214441.